Metreleptin
Also known as: A-100, Myalept, Myalepta, r-metHuLeptin, r-metLeptin, Recombinant human leptin, recombinant methionyl human leptin
Source Metreleptin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Metreleptin is a recombinant human leptin analogue administered by subcutaneous injection. It is approved in the United States and Europe for the treatment of metabolic complications in patients with generalized lipodystrophy and selected cases of partial lipodystrophy, as well as for rare leptin‑deficiency obesity syndromes. By restoring leptin signalling, metreleptin helps improve insulin sensitivity, lipid profiles, and liver steatosis in these high‑risk groups.
Mechanism of Action
Metreleptin replaces deficient endogenous leptin and binds the leptin (Ob‑R) receptor in the hypothalamus. Activation of this receptor modulates neuroendocrine pathways that suppress appetite, increase energy expenditure, and enhance peripheral insulin sensitivity. The downstream signalling improves glucose uptake, reduces hepatic lipogenesis, and normalises triglyceride metabolism, addressing the core metabolic disturbances of lipodystrophy and leptin‑deficiency states.
What the Research Shows
Clinical reviews and practice guidelines consistently report that metreleptin therapy improves the metabolic profile of patients with congenital or acquired lipodystrophy. Evidence from case series and expert consensus indicates reductions in hypertriglyceridaemia, better glycaemic control, and decreased hepatic steatosis in hypoleptinaemic individuals. Metreleptin is also listed among the few agents formally indicated for rare obesity syndromes driven by leptin deficiency. However, the literature is largely limited to observational reports and expert recommendations; randomized controlled trials are scarce, and data on hard cardiovascular outcomes remain pending.
Reported Benefits
In hypoleptinaemic lipodystrophy patients, metreleptin has been shown to lower triglyceride levels, improve insulin resistance, and reduce liver fat accumulation, leading to better overall metabolic control. The therapy is recognized as an effective option when conventional diet, lifestyle, and standard glucose‑ or lipid‑lowering drugs are insufficient, offering a disease‑specific mechanism that addresses the underlying leptin deficiency.
Limitations of the Evidence
Evidence is confined to rare lipodystrophy and leptin‑deficiency conditions; metreleptin is not approved for common obesity. Most data derive from case reports, small series, and expert consensus rather than large randomized trials. Long‑term safety, impact on cardiovascular morbidity, and efficacy in broader populations remain unproven. High cost and need for subcutaneous administration may limit accessibility.
Safety Considerations
The cited literature provides limited detail on adverse events. Reported concerns include potential injection‑site reactions and the formation of anti‑leptin antibodies, which could attenuate efficacy. Because safety data are primarily from small cohorts, clinicians are advised to monitor patients regularly for immunogenicity, allergic responses, and any unexpected metabolic changes during therapy.
How It Is Administered
Metreleptin is supplied as a sterile recombinant protein for subcutaneous injection. Dosing regimens are individualized based on patient weight and leptin levels, and the drug is typically administered daily or as directed by a specialist. The formulation is stored refrigerated and protected from light.
Routes of Administration
Goals & Uses
- Improvement of hyperglycemia and insulin resistanceMetabolic / EndocrineHigh
- Treatment of partial lipodystrophy metabolic complicationsMetabolicLow
- Reduce hypertriglyceridemiaMetabolicHigh
- Control appetite/weightWeight ManagementModerate
- Neuroendocrine restoration in hypothalamic amenorrheaReproductive EndocrinologyLow
- Reduction of hypertriglyceridemia in lipodystrophyMetabolicHigh
- Reduction of hepatic steatosisMetabolicModerate
- Decrease hepatic steatosisMetabolicModerate
- Improve glycemic controlMetabolicHigh
- Appetite and weight regulation in leptin deficiencyWeight ManagementModerate
Contraindications
- General obesity without lipodystrophyOff Label Use RiskHigh
- Active, uncontrolled infectionInfectionModerate
- Hypersensitivity to metreleptin or excipientsAllergyHigh
- Known hypersensitivity to metreleptin or excipientsAllergy / ImmunologicHigh
Adverse Effects
- Anti‑leptin antibodiesImmunologicUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Anti-metreleptin antibodies with neutralizing activityImmunologicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Lymphoma (rare)OncologicRare
- Abdominal pain / nauseaGastrointestinalUncommon
- LymphomaOncologyRare
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Immunosuppressants (e.g., cyclosporine)Low
- Oral antidiabetic agents (e.g., sulfonylureas)Moderate
- Warfarin and other narrow therapeutic index drugs metabolized by CYP450Low
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patients < 2 yearsAgeRelative
- Pediatric <2 yearsAgeAbsolute
- Patients with history of lymphomaOncologicRelative
- Severe renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionApprovedApproved: Generalized lipodystrophy, Congenital leptin deficiencyMarketed as Myalept.
- United StatesApprovedApproved: Generalized lipodystrophy, Congenital leptin deficiencyOrphan drug; dosage 0.06–0.12 mg/kg daily subcutaneously.
- United KingdomApprovedApproved: Generalized lipodystrophy, Congenital leptin deficiencySame as EU approval.
FDA approved (2014) for generalized lipodystrophy and leptin deficiency; granted orphan drug status. Approved in EU (2015) under trade name Myalept.
Evidence & Sources
- Journal ArticleModerateChakhtoura M, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateBryson C, Douglas D, Schmidt U2024-01-01T00:00:00.000000Z
- Journal ArticleModerateYordanova SG, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateMainieri F, Chiarelli F2022-01-01T00:00:00.000000Z
- Journal ArticleModerateBrown RJ, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateHussain I, Garg A2016-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions is metreleptin officially approved to treat?
Metreleptin is approved in the United States and Europe for metabolic complications of generalized lipodystrophy and for selected patients with partial lipodystrophy who have low leptin levels, as well as for rare leptin‑deficiency obesity syndromes.
How does metreleptin differ from other anti‑obesity drugs?
Unlike most anti‑obesity agents that act centrally to suppress appetite, metreleptin replaces a missing hormone, directly restoring leptin signalling. This corrects the underlying hormonal deficit rather than merely reducing food intake.
Is metreleptin effective for typical obesity?
Current evidence and regulatory approvals are limited to rare leptin‑deficiency and lipodystrophy cases. There is insufficient data to support its use in common obesity, and it is not approved for that indication.
What monitoring is required during metreleptin therapy?
Patients should be followed for metabolic parameters (glucose, lipids, liver enzymes) and screened for anti‑leptin antibodies or injection‑site reactions. Regular clinical review helps assess efficacy and detect any adverse effects early.
Can metreleptin be used in children?
Metreleptin is approved for pediatric patients with congenital generalized lipodystrophy and certain partial forms, provided they have documented hypoleptinaemia. Treatment should be managed by specialists experienced in pediatric metabolic disorders.
What is Metreleptin?
Metreleptin is a recombinant human leptin analogue administered by subcutaneous injection. It is approved in the United States and Europe for the treatment of metabolic complications in patients with generalized lipodystrophy and selected cases of partial lipodystrophy, as well as for rare leptin‑deficiency obesity syndromes. By restoring leptin signalling, metreleptin helps improve insulin sensitivity, lipid profiles, and liver steatosis in these high‑risk groups.
What is Metreleptin used for?
Metreleptin is educationally associated with: Improvement of hyperglycemia and insulin resistance, Treatment of partial lipodystrophy metabolic complications, Reduce hypertriglyceridemia, Control appetite/weight, Neuroendocrine restoration in hypothalamic amenorrhea, Reduction of hypertriglyceridemia in lipodystrophy, Reduction of hepatic steatosis, Decrease hepatic steatosis, Improve glycemic control, Appetite and weight regulation in leptin deficiency. Educational only — not medical advice.
How is Metreleptin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Metreleptin?
Reported adverse effects include: Anti‑leptin antibodies, Hypoglycemia, Injection site reactions, Headache, Anti-metreleptin antibodies with neutralizing activity, Nausea, Lymphoma (rare), Abdominal pain / nausea, Lymphoma. This list is not exhaustive — consult a qualified clinician.
Who should avoid Metreleptin?
Recorded contraindications: General obesity without lipodystrophy, Active, uncontrolled infection, Hypersensitivity to metreleptin or excipients, Known hypersensitivity to metreleptin or excipients. Consult a qualified clinician before use.